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Abstract 
 
 
Background 
Data on genetic susceptibility to sporadic gastric carcinoma have been published at a growing 
pace, but to date no comprehensive overview and quantitative summary has been available.   
 
Methods 
We conducted a systematic review and meta-analysis of the evidence on the association 
between DNA variation and risk of developing stomach cancer. To assess result credibility, 
summary evidence was graded according to the Venice criteria and false positive report 
probability (FPRP) was calculated to further validate result noteworthiness. Meta-analysis 
was also conducted for subgroups, which were defined by ethnicity (Asian vs Caucasian), 
tumor histology (intestinal vs diffuse), tumor site (cardia vs non-cardia) and Helicobacter 
Pylori infection status (positive vs negative). 
 
Results 
Literature search identified 824 eligible studies comprising 2,530,706 subjects (cases: 
261,386 [10.3%]) and investigating 2,841 polymorphisms involving 952 distinct genes. 
Overall, we performed 456 primary and subgroup meta-analyses on 156 variants involving 
101 genes. We identified 11 variants significantly associated with disease risk and assessed to 
have a high level of summary evidence: MUC1 rs2070803 at 1q22 (diffuse carcinoma 
subgroup), MTX1 rs2075570 at 1q22 (diffuse), PSCA rs2294008 at 8q24.2 (non-cardia), 
PRKAA1 rs13361707 5p13 (non-cardia), PLCE1 rs2274223 10q23 (cardia), TGFBR2 
rs3087465 3p22 (Asian), PKLR rs3762272 1q22 (diffuse), PSCA rs2976392 (intestinal), 
GSTP1 rs1695 11q13 (Asian), CASP8 rs3834129 2q33 (mixed), and TNF rs1799724 6p21.3 
(mixed), with the first nine variants characterized by a low FPRP. We also identified 
polymorphisms with lower quality significant associations (n=110). 
 
Conclusions 
We have identified several high quality biomarkers of gastric cancer susceptibility. These data 
will form the backbone of an annually-updated online resource which will be integral to the 
study of gastric carcinoma genetics and may inform future screening programs.  
 3 
Summary Box 
 
What is already known about this subject ? 
- Gastric cancer is a leading cause of death by cancer worldwide 
- Germ-line genetic variation is believed to play a key role in cancer predisposition 
- Hundreds of studies have linked specific gene polymorphisms to the risk of developing 
gastric carcinoma 
 
What are the new findings ? 
- We built up the first comprehensive database collecting the published evidence on the 
association between genetic variants and risk of gastric carcinoma 
- Data meta-analysis (using dedicated methodology) identified several high quality 
biomarkers of gastric cancer susceptibility 
- Subgroup analysis identified polymorphisms associated with specific subsets of tumor type 
(intestinal vs diffuse) and site (cardia vs non-cardia) 
- Much work is still to be done to identify gene-environment interactions 
 
How might it impact on clinical practice in the foreseeable future? 
- These data will form the backbone of an annually-updated online resource which will be 
integral to the study of gastric carcinoma genetics and may inform future screening programs.  
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Introduction 
 
Gastric carcinoma is the fifth most common cancer and the third most frequent cause of 
cancer death worldwide (1), and despite some therapeutic advances its prognosis is often 
unfavorable (2,3). Although the cascade of molecular events leading to gastric carcinogenesis 
are still largely unknown (3-5), genetic background (6,7), behavioral  factors (e.g., alcohol 
consumption, smoking habit, diet) (8,9) and infectious agents (i.e., Helicobacter Pylori [HP]) 
(10) have been associated with the risk of developing gastric carcinoma. Of note, its incidence 
shows remarkable geographic heterogeneity, the highest rates being observed in Asia, which 
has been at least in part attributed to the differences in genetic polymorphism distribution and 
prevalence of HP infection (or HP strains) in different populations (11,12).  
Germ-line variations of DNA sequence are believed to represent a key aspect of 
predisposition to most complex traits, such as cancer (13-15). As regards gastric cancer, a 
small fraction of the familial risk (approximately 3%) can be explained by rare mutations in 
high-penetrance genes such as CDH1 (encoding E-cadherin), which is associated with 
hereditary diffuse gastric cancer (16). Less than 15% of cases are believed to have familial 
clustering, most of these lacking an association with specific germ-line mutations (3,6) , 
suggesting that most familial clustering of this tumor is due to a combination of multiple 
alleles with lower penetrance (3,6).  
Numerous studies (enrolling tens of thousands of subjects) have been performed to investigate 
the role of genetic variation in gastric carcinogenesis, and many polymorphisms have been 
identified as potential risk factors for the development of this disease. Interestingly, different 
DNA variants appear to be correlated with the risk of specific gastric cancer sites (cardia 
versus non-cardia) and histological types (intestinal versus diffuse). However, the findings of 
these studies are not always consistent, and no systematic review covering all tested 
polymorphisms has been published thus far. 
The aim of this work is to fill this gap in the international medical literature by presenting the 
first systematic synopsis and meta-analysis of the available evidence in the field of DNA 
variation and the risk of sporadic gastric carcinoma, including the interaction of 
polymorphisms with both ethnicity, environmental factors (i.e. HP infection) and tumor 
features (i.e. primary cancer site and histological type). 
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Materials and methods 
 
Search strategy, eligibility criteria and data extraction 
We followed the principles proposed by the Human Genome Epidemiology Network 
(HuGeNet) for the systematic review of molecular association studies (17-19).  
Studies dealing with the association between any genetic variant and predisposition to gastric 
carcinoma in humans were considered eligible, provided that the raw data (necessary to 
calculate the risk) or summary data were available. Exclusion criteria were data published in 
abstract form only, minor allele frequency (MAF) in controls less than 1% (rare variants) and 
a sample size with fewer than 10 cases or controls.  
A two-step search strategy was adopted. First, a systematic review of original articles, reviews 
and meta-analyses analyzing the association between any genetic variant and gastric cancer 
risk was performed by searching Medline (via the PubMed gateway). The search included the 
following three groups of keywords: "cancer", "tumor" and "carcinoma"; "gastric" and 
"stomach"; "polymorphism", "single nucleotide polymorphism" and its acronym "SNP", 
"variant", "variation", "risk", and "locus". Searches were conducted using all combinations of 
at least one keyword from each group. Finally, in the light of the growing use of high-
throughput platforms for the investigation of gene variants, the expression "genome wide 
association study" and its acronym "GWAS" were also utilized as a second version of the 
third group of keywords.  
Once this search was completed, in the second phase: A) each single polymorphism was used 
as a keyword to further refine the search; B) cited references from eligible articles were also 
searched; C) publicly-available databases dedicated to genotype/phenotype associations were 
searched (i.e. Database of Genotypes and Phenotypes [dbGaP], 
http://www.ncbi.nlm.nih.gov/gap; Genome Medicine DataBase of Japan [GeMDBJ], 
http://gemdbj.nibio.go.jp, and HuGeNet Phenopedia, 
http://www.hugenavigator.net/HuGENavigator/startPagePhenoPedia.do); D) authors were 
contacted whenever unreported data were potentially useful to enable the inclusion of the 
study into the systematic review or to rule out data published in different articles but 
regarding overlapping series.  
For analysis purposes, the database, which will be updated annually and will be publicly 
available at http://www.mmmp.org (20), was frozen in May 2014.  
Additional methodology details are available as online Supplementary Information. 
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Statistical analysis 
Odds ratios (OR) and corresponding 95% confidence intervals (CI) were used to assess the 
strength of association between each genetic variant and cancer risk. Per-allele OR were 
calculated for each study and each polymorphism, assuming an additive (co-dominant) 
genetic model. This approach was chosen for the following reasons: A) for some studies 
(including GWAS), only per-allele OR were available; B) the additive model is widely used 
as a conservative choice between the recessive and the dominant model; C) one model does 
not require adjustment for multiple hypotheses (which is necessary when different models are 
tested); D) methods that let the data dictate the genetic model (e.g. the model-free approach 
(21)) require raw data on genotype distributions (which were unavailable for some studies); 
E) when large sample sizes are available (as expected in a systematic review and meta-
analysis), non-additive models rarely identify high quality associations unidentified by the 
additive model: therefore the co-dominant model is largely used in genetic association 
synopses (22-24). 
Summary OR were calculated by performing random-effects meta-analysis (using the inverse 
variance method), which reduces to a fixed-effect meta-analysis when no between-study 
heterogeneity exists. The choice of this model was suggested mainly by the heterogeneity 
typically expected in genetic association studies. 
For each variant, a meta-analysis was performed if at least three independent datasets were 
available. As regards GWAS, if data were available, discovery and replication phases were 
considered as separate datasets.  
Subgroup analysis by ethnicity (Asian vs Caucasian/Other), primary tumor site (cardia vs 
non-cardia), histological subtype (intestinal vs diffuse) and HP status (positive vs negative) 
was performed if data permitted.  
Population attributable risk (PAR) was calculated using the Levin's formula: P (RR – 1) / [1 + 
P (RR – 1)], where P is the proportion of controls exposed to the genotype of interest and the 
relative risk (RR) was estimated using the summary estimates (OR) calculated by meta-
analysis. 
The alpha level of significance was set at 0.05, except for the Harbord test and Q-test (0.10), 
and the Hardy-Weinberg equilibrium test (0.01). 
All statistical analyses were performed with STATA 11.0/SE (StataCorp LP, College Station, 
Texas, USA).  
 
Assessment of cumulative evidence 
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In order to evaluate the credibility of each nominally statistically significant association 
identified by meta-analysis, we applied the Venice criteria (18,19). Briefly, credibility level 
was defined based upon the grade (A=strong, B=moderate or C=weak) of three parameters:  
1) Amount of evidence, roughly depending upon the study sample size, was graded by the 
sum of cases and controls expressing the risk allele: grade A, B or C were assigned for more 
than 1000, 100-1000 and less than 100, respectively. 
2) Replication of the association was graded based on the amount of heterogeneity: grade A, B 
or C were assigned for I-squared less than 25%, 25-50% and over 50%, respectively. 
3) Protection from bias was graded as A if there was no observable bias (bias was unlikely to 
explain the presence of the association), B if bias could be present, or C if bias was evident. 
Assessment of protection from bias also considered the magnitude of association: a score of C 
was assigned to an association with a summary OR less than 1.15 (or greater than 0.87 in case 
of protective effect) (18).  
According to these criteria, the credibility level of the cumulative evidence was defined as 
high (A grades only), low (one or more C grades) or intermediate (all other combinations). 
In addition to the Venice criteria, we assessed the noteworthiness of significant findings by 
calculating the false positive report probability (FPRP) (25), which is defined as the 
probability of no true association between a genetic variant and disease (null hypothesis) 
given a statistically significant finding. The FPRP is based not only on the observed P-value 
of the association test but also on the statistical power of the test and on the prior probability 
that the molecular association is real (according to a Bayesian approach). We calculated FPRP 
values for two levels of prior probabilities: at a low prior (10E-3) that would be similar to 
what is expected for a candidate variant, and at a very low prior (10E-6) that would be similar 
to what would be expected for a random variant. To classify a significant association as 
"noteworthy", we used a FPRP cut-off value of 0.2 (25). 
For each non significant meta-analysis, we assessed the quality of summary evidence for no 
association (22). To this aim, we calculated the power of detecting a non-negligible 
association (i.e., OR ≥1.15 or ≤0.87) for a hypothetical study with sample size equal to the 
combined sample sizes of the studies included in the meta-analysis (with an alpha level of 
significance set at 5%). If the power were ≥90%, no between-study heterogeneity were found 
(I-squared <25%) and no bias were detected, we considered the level of cumulative evidence 
high (i.e., sufficient to rule out any meaningful relationship between that variant and gastric 
cancer risk). Either power <80%, or significant between-study heterogeneity or detection of 
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bias (or any combination of them) indicated a low level of evidence. In all other cases, the 
level of evidence for no association was considered intermediate. 
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Results 
 
Characteristics of eligible studies 
The database with the main features and findings of all eligible studies is available online 
(Supplementary Table 1). 
We identified 824 eligible articles (Supplementary Figure 1), comprising 2,530,706 subjects 
(cases: 261,386 [10.3%], range: 13-3,632, mean: 316). More than 95% of these studies 
(788/824) were published after the year 2000 (with a steep positive trend over time, see 
Supplementary Figure 2). 
According to the prevalent ancestry (the race of at least 80% of the enrolled subjects), two 
thirds of the studies were Asian (n=555, 67%). 
Based on the design, the majority of the studies were hospital-based case-control studies 
(n=494, 60%), the remaining being population-based case-control studies, 24 of which were 
case-control studies within the frame of cohort prospective studies. Data from three GWAS 
were also available (26-28). 
Less than half of the eligible studies specified the histological subtypes (intestinal vs diffuse) 
of gastric carcinoma (n=329, 40%), the site (cardia vs non-cardia) of the primary tumor 
(n=338, 41%), and the status (positive vs negative) of gastric Helicobacter Pylori infection 
(n=102, 12%).  
Overall, data on 2,841 polymorphisms involving 952 distinct genes were available. Variation 
consisted mainly of SNP (n=2,784; 97%), followed by insertions/deletions (n=34), variable 
number of tandem repeats (n=16) and polymorphisms revealed by a specific change in 
phenotype (n=7, such as presence/absence of enzymatic activity). These genetic variants were 
located in the DNA upstream the "relevant" (meant as physically closest) gene (including the 
promoter region) (n=508), downstream the "relevant" gene (n=215), in introns (n=1,461), in 
exons (n=378), in the 5'-UTR (n=56) and the 3'-UTR (n=182). Among the exonic SNPs, the 
functional effects were generally missense (n=229) and synonymous coding changes (n=127), 
with the remaining being stop-gain, frameshift or splicing variations (n=5). 
Distribution of variants (and significant associations with gastric cancer risk) across 
chromosomes are depicted in Supplementary Figure 3.Of note, most of the variants tested 
are located on chromosome 1, no variant on chromosome Y has been ever investigated, and 
only three variants in mitochondrial DNA have been studied.   
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Meta-analysis findings 
The results of data meta-analysis are comprehensively reported online (Supplementary 
Table 2). At least three independent datasets were available for 156 variants across 101 
genes, which allowed us to perform 456 meta-analyses. Of these, 164 were primary meta-
analyses and 292 meta-analyses of subgroups as defined by  ethnicity (Caucasian [n=44 meta-
analyses] versus Asian [n=77]), cancer histological subtype (intestinal [n=41] versus diffuse 
[n=40]), primary tumor site (cardia [n=34] versus non-cardia [n=36]) and HP infection status 
(positive, [n=12] versus negative [n=8]).  
The number of datasets meta-analyzed ranged from 3 to 68, the mean number being 7. Based 
on the number of datasets, the ten most studied variants were the following: IL1B rs16944 
(data setes, n=68), IL1RN rs2234663 (n=60), GSTM1 wild/null (n=50), IL1B rs1143627 
(n=47), GSTT1 wild/null (n=40), TNF rs1800629 (n=38), TP53 rs1042522 (n=33), MTHFR 
rs1801133 (n=29), IL10 rs1800896 (n=29), and IL10 rs1800872 (n=25). 
The number of subjects (cases plus controls) enrolled in the 456 meta-analyses ranged from 
477 to 1,496,612 (median: 3,704). Based on the number of subjects, the ten most studied 
variants were the following: ABO rs8176719/rs8176746/rs8176747 (n=1,496,612 individuals; 
however, nearly 99% of these subjects were controls), PSCA rs2294008 (n=42,274), PLCE1 
rs2274223  (n=33,219), IL1B rs16944 (n=29,789), PRKAA1 rs13361707 (n=25,319), 
GSTM1 wild/null (n=25,222), IL1RN rs2234663 (n=24,930), MUC1 rs4072037 (n=23,024), 
GSTT1 wild/null (n=22,008), and IL1B rs1143627 (n=20,922). 
Of the 456 meta-analysis performed, 121 (26%) resulted nominally statistically significant  
(P-value <0.05), the remaining 335 being non-significant. Among the significant associations 
identified by meta-analysis, the level of summary evidence was high, intermediate or low in 
11 (9%), 38 (31%) and 72 (60%) analyses, respectively. Between-study heterogeneity was the 
most frequent single cause of non-high quality level of evidence (12/38 intermediate level, 
56/72 low level). Considering all meta-analyses, the FPRP was optimal (<0.2) at the 10E-3 
and 10E-6 level for 28/121 and 14/121 contrasts, respectively. Amongst the high quality 
associations, the FPRP was optimal at the 10E-3 and 10E-6 level for 9/11 and 5/11 contrasts, 
respectively.  
The details of significant associations characterized by a high or intermediate level of 
summary evidence are reported in Table 1. These polymorphisms, arranged upon their gene 
main function, are shown in Figure 1. Combinations of variants to predict gastric cancer risk 
are reported in Table 2.  
High quality significant associations emerged from data meta-analysis are discussed below.  
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MUC1 rs2070803 
Located on chromosome 1q22, rs2070803 is a G>A SNP downstream of both MUC1 and 
TRIM46. MUC1 codes for mucin-1, a cell surface glycoprotein which has been repeatedly 
reported to be involved in the carcinogenesis of different tumors (29), including gastric cancer 
(30,31),  and is also widely used in the clinical setting as a tumor marker known as CA15.3,. 
TRIM46 codes for the tripartite motif-containing protein 46, a zinc-finger containing protein 
of still uncertain function recently associated with serum urate concentrations (32). MUC1 is 
located downstream of the TRIM46 gene: these two genes are part of a cluster of genes 
(including also KRTCAP2, THBS3, MTX1, PKLR and HCN3) located in a region of strong 
linkage disequilibrium (LD), and are transcribed in opposite directions (i.e., convergently). 
Since TRIM46 is not expressed in gastric mucosa (33), rs2070803 (whose functional effect is 
unknown) might be a tagging SNP for variants in other genes located in this LD block, such 
as MUC1,  which are associated with gastric carcinogenesis.  
The primary meta-analysis (including 8,789 subjects) showed a statistically highly significant 
association between this SNP and gastric cancer risk (summary OR: 0.66, 95%CI: 0.59-0.74, 
P-value=2.55E-13); however, the level of evidence was intermediate due to between-study 
heterogeneity. When subgroups were considered, the meta-analysis of six datasets (five 
deriving from two GWAS) including 7,279 subjects (all of Asian ancestry) demonstrated that 
the rare A allele was associated with a reduced risk of developing the diffuse subtype of 
gastric carcinoma (summary OR: 0.585, 95%CI: 0.526-0.650, P-value=2.24E-23), with a high 
level of cumulative evidence as per the Venice criteria and a low false positive report 
probability (FPRP) at both prior probability levels (10E-3 and 10E-6) (see Table 1). 
Noticeably, this SNP did not result to be associated with intestinal subtype gastric carcinoma 
(summary OR: 0.759, 95%CI: 0.568-1.012, P-value= 0.061), suggesting that rs2070803 might 
be specifically linked to diffuse gastric cancer.  
In our synopsis, data on a second MUC1 variant (rs4072037) were meta-analyzed, but the 
association resulted significant only with a low level of evidence.  
 
MTX1 rs2075570 
This intronic A>G SNP in the MTX1 gene (on chromosome 1q22) is in strong linkage 
disequilibrium with the previously described MUC1 rs2070803. MTX1 encodes metaxin-1, a 
mitochondrial outer membrane protein involved in apoptosis (34,35). 
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According to the primary meta-analysis (including 8,189 subjects), there was a highly 
significant association, although the level of evidence was intermediate due to between-study 
heterogeneity. Upon subgroup meta-analysis, data from five datasets (all deriving from two 
GWAS) including 6,902 subjects (all of Asian ancestry) showed that the G allele was 
associated (with a high level of evidence) with a reduced risk of developing the diffuse 
subtype of gastric carcinoma (summary OR: 0.587, 95%CI: 0.525-0.655, P-value=3.00E-21), 
with a low FPRP at both prior probability levels. This SNP was not significantly associated 
with the intestinal subtype of gastric carcinoma (summary OR: 0.848, 95%CI: 0.643-1.117, P-
value= 0.241), suggesting that rs2075570 might be specifically linked to diffuse gastric 
cancer.  
 
PKLR rs3762272 
This intronic A>G SNP of the PKLR gene (chromosome 1q22) codes for pyruvate kinase 
(liver and red blood cell isoenzyme). This enzyme catalyzes the transphosphorylation of 
phosphoenolpyruvate into pyruvate and ATP, the rate-limiting step of glycolysis (36) that is 
the key metabolic event underlying the Warburg effect in malignant cells (37).  
Upon primary meta-analysis (including 5,750 subjects) the association with this SNP was 
statistically marginal with a high degree of heterogeneity which made the level of evidence 
low. Instead, the meta-analysis of three datasets (all deriving from one GWAS) including 
4,463 subjects (all of Asian ancestry) showed that the G allele is associated (with a high level 
of evidence) with a reduced risk of developing the diffuse subtype of gastric carcinoma 
(summary OR: 0.710, 95%CI: 0.631-0.799, P-value=1.42E-08), with a low FPRP at the 
higher prior probability level (10-3). Noticeably, this SNP did not result to be associated with 
intestinal subtype gastric carcinoma (summary OR: 0.927, 95%CI: 0.717-1.197, P-value= 
0.559), suggesting that rs3762272 might be specifically linked to diffuse gastric cancer. 
 
PSCA rs2294008 and rs2976392 
The C>T SNP rs2294008 is located in exon 1 of PSCA (chromosome 8q24.2) and leads to a 
frameshift variation that causes a change in the starting codon and is associated with reduced 
gene transcription (26). PSCA was first identified as a prostate-specific antigen overexpressed 
in prostate cancer (38), but was then found to also be expressed by other tumor types as well 
as some normal tissues (including stomach and bladder epithelial cells) (39). PSCA protein 
product can inhibit proliferation of gastric cancer cells (26), but its role in carcinogenesis 
appears complex and is still debated (40).  
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The primary meta-analysis of 15 datasets (42,274 subjects) revealed a highly significant 
association with disease susceptibility; however, the level of summary evidence was low due 
to between-study heterogeneity. When subgroup analysis was performed, a similar situation 
occurred with ancestry and histotype subgroups. In contrast, seven datasets (none from 
GWAS) including 12,665 subjects (both Asian and Caucasian ancestry) showed that the T 
allele is associated with a high level of evidence with an increased risk of developing the non-
cardia subtype of gastric carcinoma (summary OR: 1.329, 95%CI: 1.254-1.408, P-
value<1.00E-20), with a low FPRP at both prior probability levels. SNP rs2294008 was not 
associated with cardia subtype gastric carcinoma (summary OR: 1.119, 95%CI: 0.933-1.342, 
P-value= 0.225), suggesting that this SNP might be specifically linked to non-cardia gastric 
cancer. 
Other meta-analyses have recently confirmed the association between gastric cancer and 
rs2294008 (41,42) (43,44), a variant also associated with the risk of bladder cancer (41,45). 
The intronic A>G polymorphism rs2976392 (whose functional effect is unknown) is in strong 
linkage disequilibrium with the previously discussed PSCA rs2294008.  
Primary meta-analysis (16,338 subjects) revealed a highly significant association, but as with 
SNP rs2294008, the resultant level of evidence was low due to between-study heterogeneity. 
Upon subgroup meta-analysis, data from four datasets (two deriving from a GWAS) including 
7,045 subjects (only Asian ancestry) showed that the G allele is associated (with a high level 
of evidence) with a decreased risk of developing the intestinal subtype of gastric carcinoma 
(summary OR: 0.808, 95%CI: 0.751-0.870, P-value=1.42E-08), with a low FPRP at the 
higher prior probability levels. This variant was also associated with disease risk in patients 
with diffuse subtype stomach carcinoma (summary OR: 0.619, 95%CI: 0.549-0.697, P-
value=4.22E-15), although for this subgroup the level of evidence was low due to between-
study heterogeneity. 
We could meta-analyze the data regarding a third PSCA polymorphism (rs2976391) that 
resulted significantly associated with stomach cancer risk with an intermediate level of 
summary evidence.  
 
PRKAA1 rs13361707 
This T>C SNP (whose functional effect is unknown) is located in the first intron of PRKAA1 
(chromosome 5p13), a gene encoding the catalytic alpha subunit of AMP-activated protein 
kinase (AMPK). This enzyme is a cellular energy sensor that maintains energy homeostasis 
(46) and might be involved in cancer development since its activation is associated with 
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decreased phosphorylation of mammalian target of rapamycin (mTOR) and S6 kinase, which 
in turn causes a general reduction in mRNA translation and protein synthesis (47,48).  
The primary meta-analysis (25,319 subjects) demonstrated a highly significant association 
between this variant and gastric cancer, although the level of evidence was low due to 
between-study heterogeneity. Nevertheless, restricting the meta-analysis to five datasets (three 
from a GWAS, all of Asian ancestry) comprising 15,478 subjects supported with a high level 
of evidence the link between the C allele of rs13361707 and an increased risk of non-cardia 
subtype gastric cancer (summary OR: 1.406, 95%CI: 1.334-1.482, P-value<1.00E-20) with a 
low FPRP at both prior probability levels. rs13361707 resulted associated also to cardia 
subtype gastric cancer, although this evidence was of intermediate level due to potential 
leading study bias (linked to a study (49) identified by the leave-one out sensitivity analysis). 
 
PLCE1 rs2274223 
This A>G SNP located in exon 26 of the PLCE1 gene (chromosome 10q23) causes a 
missense variation (His>Arg) in the protein product named phospholipase-C epsilon-1. This 
enzyme catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate to generate two 
second messengers (i.e. inositol 1,4,5-triphosphate [IP3] and diacylglycerol [DAG]) that 
subsequently regulate various processes affecting cell growth, differentiation, and gene 
expression (50). Notably, recent investigations have demonstrated that PLCE1 might have a 
role in gastric carcinogenesis as it is overexpressed in precancerous chronic atrophic gastritis 
tissues and stomach carcinoma (as compared with normal gastric tissues) (51), and its 
inhibition has therapeutic potential in a xenograft model (52). Nevertheless, the ultimate 
function of PLCE1 in cancer development is still debated, since this molecule is 
downregulated in other tumors and shows a tumor suppressor activity in some animal models  
(53). 
When all available datasets were included in the meta-analysis (n=11, subjects: 33,219; both 
Asian and Caucasian ancestry), the G allele was significantly associated with an increased 
risk of gastric cancer (summary OR: 1.219, 95%CI: 1.081-1.373, P-value= 0.001). However, 
the level of evidence was low (due to a high degree of between-study heterogeneity) and the 
FPRP was high at both prior probability levels. 
In contrast, the meta-analysis of five datasets (two from a GWAS) composed of 21,366 
subjects (Asian ancestry only) showed the G allele of rs2274223 to be associated (with a 
strong level of evidence) with an increased risk of cardia subtype gastric cancer (summary 
OR: 1.565, 95%CI: 1.486-1.648, P-value<1.00E-20) with a low FPRP at both prior 
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probability level. When the only Caucasian study is included (54), this association is still 
highly significant (summary OR: 1.539, 95%CI: 1.386-1.709, P-value: 8.88E-16) but the level 
of evidence becomes low due to between-study heterogeneity. Interestingly, rs2274223 was 
not associated with non-cardia gastric cancer with a high level of evidence, which suggests 
that this SNP is specifically linked to the carcinomas originating in the cardia region of the 
stomach. 
In the present work, data on other four PLCE1 variants were meta-analyzed (rs11187842, 
rs3765524, rs3781264 and rs753724), with only one of them significantly associated with 
disease risk (rs3765524), albeit with a low level of summary evidence. 
 
TGFBR2 rs3087465 
This G>A SNP is located in the promoter region of TGFB2 (chromosome 3p22), which 
encodes the transforming growth factor beta receptor 2, a transmembrane Ser/Thr protein 
kinase protein that forms a heterodimeric complex with TGFBR1 and binds TGFB ligands. In 
turn, this mediates a variety of  physiological and pathological processes including cell cycle 
arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and 
differentiation, wound healing, extracellular matrix production, immunosuppression, 
epithelial-mesenchymal transition, as well as carcinogenesis in different tumor models 
(55,56), including gastric cancer (57,58).  
The meta-analysis of the four available datasets (subjects: 4,670; Asian ancestry only) showed 
a highly significant association between the minor allele (A) of rs3087465 and a decreased 
risk of gastric cancer (summary OR: 0.691, 95%CI: 0.620-0.769, P-value= 1.54E-11). This 
evidence was of a high level and the FPRP was low at the higher prior probability level. No 
subgroup analysis could be performed due to the lack of permissive data. 
 
GSTP1 rs1695 
This A>G SNP is located in exon 5 of GSTP1 (chromosome 11q13) and causes a missense 
variation (Ile>Val) in the encoded protein glutathione S-transferase pi-1, which leads to a 
lower activity of the enzyme. GSTP1 belongs to a family of enzymes that play a key role in 
detoxification of a variety of endogenous and exogenous compounds by catalyzing their 
conjugation with reduced glutathione (59). Given its importance in the maintenance of 
integrity of different cell components (e.g. membranes and DNA), GSTP1 has been 
extensively investigated in the field of carcinogenesis (60). 
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The primary meta-analysis of all 20 datasets (subjects: 11,258; both Asian and Caucasian 
ancestry) showed no association between the minor allele (G) of rs1695 and gastric cancer 
risk, with low level evidence (due to between-study heterogeneity). However, when the meta-
analysis was performed separately in Asian and Caucasian subjects, a significant association 
of high quality was observed only in the former subgroup (summary OR: 1.191, 95%CI: 
1.092-1.299, P-value: 7.88E-05), with a low FPRP at the higher prior probability level, with 
no association being demonstrated in the other subgroups. 
 
CASP8 rs3834129 
This variant consists of a 6-nucleotide deletion in the promoter region of CASP8 
(chromosome 2q33), which leads to a reduced gene transcription. The gene product, named 
caspase-8, is a cysteine-aspartic acid protease and is a pivotal mediator of programmed cell 
death, In brief, once activated by death receptors, it activates both caspase-3 (which in turn 
activates enzymes with DNAse activity) and Bid (which initiates the mitochondrial apoptotic 
pathway) (61). Given the importance of malignant cell escape from apoptosis, the role of 
CASP8 in carcinogenesis has been extensively investigated in different tumor models (62-65). 
The meta-analysis of the three datasets (n=1,701; both Asian and Caucasian ancestry) 
revealed that the minor allele (deletion) of rs3834129 is associated, with a high level of 
evidence, with a decreased risk of gastric cancer (summary OR: 0.732, 95%CI: 0.617-0.869, 
P-value: 3.48E-04), although the FPRP was high at both prior probability levels. Available 
data did not enable us to perform subgroup analysis. 
 
TNF rs1799724 
This C>T SNP is located in the promoter region of the TNF gene (chromosome 6p21.3), 
which encodes a TNF superfamily member known as tumor necrosis factor. This is a pro-
inflammatory cytokine that plays an important role in the immune response to infectious 
agents but is also involved in the pathogenesis of autoimmune diseases (66) and presents 
pleiotropic functions in cancer development and progression (67,68). 
Primary meta-analysis of the ten available datasets (n=5,953; both Asian and Caucasian 
ancestry) showed a significant association between the minor allele (T) of rs1799724 and an 
increased risk of gastric cancer (summary OR: 1.173, 95%CI:1.047-1.314, P-value: 
0.006), characterized by a high level of evidence but also by a high FPRP at both prior 
probability levels. This association remained significant when the meta-analysis was 
restricted to Asian subjects (intermediate level of evidence), but not when it was restricted to 
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the other two subgroups (Caucasian subjects and non-cardia subtype) for which data were 
available (low level of evidence). 
Another four TNF polymorphisms (rs1800629, rs1799964, rs1800630 and rs361525) have 
been meta-analyzed in this synopsis, but only one (rs1800629) was significantly associated to 
gastric cancer risk with an intermediate level of evidence.  
 
Non-significant associations 
Among 335 non-significant primary or subgroup meta-analyses, the level of evidence for lack 
of association was high, intermediate or low for 5 (1.5%), 21 (6.3%) and 309 (92.2%) 
analyses, respectively (Supplementary Table 2). The most frequent single cause of non-high 
level of evidence was insufficient statistical power (130/330), followed by between-study 
heterogeneity (71/330). 
The details of non-significant associations characterized by a high or intermediate level of 
evidence are reported in Table 3. 
 
 
 18 
Discussion 
 
In this article, we describe the results of the first systematic synopsis and meta-analysis (with 
evaluation of the quality of the cumulative evidence) in the field of genetic predisposition to 
sporadic gastric carcinoma. We found that out of 2,841 variants investigated, 11 
polymorphisms in ten genes were associated with susceptibility to gastric cancer in general or 
to the susceptibility of specific subgroups identified by ancestry (Asian vs Caucasian), 
primary tumor site (cardia vs non-cardia) and histological subtype (intestinal vs diffuse), with 
a high level of evidence. Of note, for seven of these 11 variants (MUC1 rs2070803, MTX1 
rs2075570, PKLR rs3762272, PRKAA1 rs13361707, TGFBR2 rs3087465, CASP8 
rs3834129, TNF rs1799724) this is the first time that a meta-analysis confirms their 
association with risk of developing gastric carcinoma. 
 
These findings provide investigators with a robust platform of genetic information useful to 
elucidate the molecular mechanisms underlying the pathogenesis of gastric carcinoma. For 
instance, our data support the hypothesis that the genetic information contained in 
chromosome 1 might play a predominant role in the susceptibility of this disease: in fact, the 
highest number of statistically significant contrasts with a high or intermediate level of 
evidence are located in this chromosome (16/49, 32.6%). Interestingly, these twelve variants 
are located in the long chromosomal arm and nine of them belong to a region (chromosomal 
band 1q21-22) repeatedly reported to be affected by chromosomal aberrations (e.g. copy 
number variations) in a range of tumors (such as breast (69,70), ovarian (70), hepatocellular 
(71,72), lung (73), esophageal (74), cervical (75) and oral (76) carcinomas, neuroblastoma 
(77), and liposarcoma (78)), including stomach sporadic carcinoma (79). Moreover, GWAS 
have recently identified this region as a susceptibility locus for cutaneous melanoma (80) and 
testicular germ cell tumor (81). Therefore, this region of the genome represents a promising 
target for more extensive investigations in the field of gastric cancer research. On the other 
side, this  synopsis also points out DNA regions scarcely investigated in the literature and thus 
worth new efforts. 
By arranging our data upon (main) gene function, another interesting observation is that the 
majority of statistically significant results with high or intermediate level of evidence regard 
variants of genes involved in immunity/inflammation or adhesion/invasiveness (24/49, 
48.9%). This finding is in line with the pivotal role of HP infection in the development of 
gastric cancer (10). In particular, our data draw the attention to polymorphisms that might 
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explain the still enigmatic relationship between the high prevalence of HP infection in the 
general population (up to 70% (82)) and the relatively low gastric cancer incidence (up to 50 
cases/100,000/year (1)) (11). Unfortunately, the scarcity of published data on the interaction 
between HP status and DNA variants only allowed us to perform 20 HP specific subgroup 
meta-analyses (out of 456 meta-analyses) and did not enable us to yield any meaningful 
results.  
 
The 11 common low-penetrance variants identified by our meta-analysis for their strong 
evidence of association with gastric cancer could also be used to set up prediction algorithms 
for stratifying disease risk within the frame of targeted screening programs (83-87).  
Since it is well recognized that each genetic locus confers a small contribution to the overall 
risk of a polygenic disease such as cancer, it is daunting to consider any single polymorphism 
as a test for routine clinical use (83). In our synopsis, the mean PAR of the 11 high-quality 
biomarkers was 18%. Nevertheless, their combination can raise the fraction of the disease 
burden attributable to genetic variation and thus improve the predictive power of tests based 
on genetic profiles, as suggested for other tumors such as breast (84), colorectal (85) and 
prostate cancer (86). 
In this regard, haplotype studies have already shown the potential of polymorphism 
combination in the identification of subjects at high risk of gastric carcinoma (88-90) by 
showing odds ratios higher than 2 (or lower than 0.5) and PAR up to 60%. However, the 
published data did not enable us to perform any meta-analysis since a minimum of three 
independent datasets was not available for any of the haplotypes studied so far. 
To provide readers with an idea of the predictive potential of combining multiple 
polymorphisms, we calculated four joint-PAR (using seven variants unrelated to one other as 
defined by a pairwise correlation coefficient r2 < 0.1), whose values ranged from 21.3% 
through 51.2%. Of note, these joint-PAR would lead to a number needed to screen (number of 
people who must be tested to prevent one case of gastric carcinoma (91)) that varies from 22 
through 990, depending also on the lifetime risk of disease (range: 1% to 5%) (Table 2).  
 
In this synopsis, other interesting results came from subgroup meta-analysis. First, we 
confirmed the difference between the results obtained in populations of different ancestry (see 
Supplementary Information and Supplementary Figures 4 and 5), which support the 
hypothesis that the molecular pathway to gastric cancer susceptibility is not necessarily the 
same across different ethnicities and underscore the need for race specific risk prediction 
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tools. Moreover, our results also show some evidence as regards the genetic pathways specific 
for some gastric cancer subtypes (see Supplementary Information and Supplementary 
Figures 6 and 7). Considering the different epidemiology and aggressiveness of different 
subsets of the disease (8,92), these subgroup specific findings might help elucidate the 
molecular mechanisms underlying not only the development but also the progression of 
gastric cancer subtypes. 
 
As regards the already existing literature, the past decade has witnessed the publication of a 
growing number of systematic reviews and meta-analyses addressing genetic predisposition to 
a variety of tumor types (93,94). In the field of stomach cancer, we found 243 such type of 
publications, which almost always take into consideration single polymorphisms, 
polymorphisms of single genes or variants of genes belonging to the same cell pathway. In a 
single article, published in 2009, the authors extend their analysis to 225 variants across 95 
genes by collecting the data from 203 primary studies, and report the findings of 61 primary 
or subgroup meta-analyses (the only subgrouping variable being ethnicity) (95). A previous 
similar work, published in 2002, gathered a much lower number of primary studies (n=31) 
(96). Finally, other investigators have reviewed the meta-analyses regarding the association 
between genetic variations and gastric cancer (97) or different tumor types including gastric 
cancer (14).  
The present work - which outnumbers the previously published literature by number of 
articles retrieved, variants investigated, meta-analyses performed, subgroups considered and 
subjects enrolled - is characterized not only by a truly comprehensive search of the literature 
in this field, but also by the effort to grade the quality of the cumulative evidence based on 
criteria specifically set up by a panel of international experts (i.e. Venice criteria). Moreover, 
for each statistically significant meta-analysis, we calculated the FPRP in order to further 
increase the information provided to readers on the reliability of the findings generated by our 
analysis. This way, we provide an updated and more critical summary of the available 
evidence compared to the already existing literature in this field.  
 
We must also recognize the limits of this synopsis. Firstly, despite our efforts to be 
comprehensive and accurate, we might have missed some relevant articles and may have 
included partially overlapping series.  
Secondly, some series have been utilized for more than one meta-analysis, which potentially 
raises the statistical issue of type I error inflation. However, following the implementation of 
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the FPRP method, this occurrence should be minimized; moreover, even after Bonferroni 
correction for multiple testing, all 11 high quality biomarkers identified by our meta-analysis 
would remain statistically significant.  
Thirdly, we considered only one genetic model (i.e. additive, which generates per allele odds 
ratios), as explained in the Methods section. The aim of this work was not to define the best 
genetic model for some specific well established biomarkers but rather to quantitatively 
summarize the evidence regarding hundreds of variants, a job that is best done using a 
conservative approach such as the additive model. In addition, no genotype data are available 
for a large number of variants. Also, the use of different models in primary and subgroup 
meta-analyses would have approximately tripled the number of meta-analyses, which would 
have in turn amplified the issue of type I error inflation.  
Fourthly, as previously mentioned, the paucity of data on gene-environment interactions did 
not allow us to thoroughly investigate potential sources of between-study heterogeneity, with 
special regard to HP infection status. For other potential effect modifiers, such as smoking, 
alcohol and dietary habits (though they are less important than HP infection (8,9)), available 
data were so scarce that we could not even take them into consideration. Although some 
articles reported odds ratio values adjusted by one or more confounding factors, this was not 
always the case. The lack of data, coupled with the fact that adjusting covariates of 
multivariable logistic regression analysis differed in most circumstances, prevented us from 
implementing this information in our analyses, which are exclusively based on raw 
(unadjusted) odds ratios. 
Finally, we must remind readers that some polymorphisms (e.g. those located on chromosome 
1q22) we found associated with gastric cancer risk are in strong linkage disequilibrium with 
each other, which might imply they actually represent a single signal; moreover, some of our 
result interpretation - such as the clues on genes involved in the molecular pathways leading 
to gastric carcinogenesis - rely on the a priori assumption that the relevant gene of extra-genic 
variants is the nearest gene. Clearly, fine mapping and functional studies are required to 
identify the most likely causal variants and the genes they control before any predictive 
genetic tool is set up and any therapeutic target is considered, which highlights once again the 
burden of work still to be done in this field.  
 
In conclusion, we performed the first systematic review and meta-analysis of the evidence 
linking DNA variation to the development of gastric carcinoma. We hope that this 
unprecedented collection of data might represent a useful platform for investigators involved 
 22 
in this research field not only for designing future studies but also to create a continuously 
updated databank dedicated to the genetic basis of this disease, a long standing gap in the 
initiatives of the international scientific community.  
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Figure 1 legend 
 
Genetic variants statistically significantly associated with risk of gastric carcinoma (with a 
high or intermediate level of evidence according to the Venice criteria) arranged by (main) 
gene function. 
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Table 1. Meta-analysis results: genetic variants significantly associated with gastric cancer risk with a high or intermediate level of summary evidence 
 
Gene Variant ID Chr 
Risk 
Allele 
Datasets Cases Controls Subgroup sOR LL UL P-value 
Venice 
criteria 
Level of 
Evidence 
FPRP 
(10E-3) 
FPRP 
(10E-6) 
MUC1 rs2070803 1 A 6 2376 4903 Diffuse 0.585 0.526 0.650 <1.00E-20 AAA High 0.00 0.00 
MTX1 rs2075570 1 G 5 2299 4603 Diffuse 0.587 0.525 0.655 <1.00E-20 AAA High 0.00 0.00 
PRKAA1 rs13361707 5 C 5 7587 7891 Non-cardia 1.406 1.334 1.482 <1.00E-20 AAA High 0.00 0.00 
PLCE1 rs2274223 10 G 5 4869 16497 Cardia 1.565 1.486 1.648 <1.00E-20 AAA High 0.00 0.00 
PSCA rs2294008 8 T 7 5690 6975 Non-cardia 1.329 1.254 1.408 <1.00E-20 AAA High 0.00 0.00 
TGFBR2 rs3087465 3 A 4 2323 2347 Asian 0.691 0.620 0.769 1.54E-11 AAA High 0.00 0.53 
PKLR rs3762272 1 G 3 1362 3101 Diffuse 0.710 0.631 0.799 1.42E-08 AAA High 0.03 0.97 
PSCA rs2976392 8 G 4 2602 4443 Intestinal 0.808 0.751 0.870 1.42E-08 AAA High 0.00 0.36 
GSTP1 rs1695 11 G 11 2425 4731 Asian 1.191 1.092 1.299 7.88E-05 AAA High 0.12 0.99 
CASP8 rs3834129 2 del 3 616 1085 Mixed 0.732 0.617 0.869 3.48E-04 AAA High 0.93 1.00 
TNF rs1799724 6 T 10 2136 3817 Mixed 1.173 1.047 1.314 0.006 AAA High 0.89 1.00 
PSCA rs2294008 8 T 13 7380 26388 Intestinal 1.284 1.206 1.367 5.33E-15 ABA Intermediate 0.00 0.00 
TRIM46 rs3814316 1 C 3 1362 3101 Diffuse 0.582 0.506 0.670 3.71E-14 AAB Intermediate 0.00 0.79 
THBS3 rs2066981 1 C 3 1362 3101 Diffuse 0.585 0.507 0.674 1.57E-13 AAB Intermediate 0.00 0.22 
ABO rs8176719 9 A (vs O) 15 8737 1069256 Caucasian 1.225 1.161 1.293 1.92E-13 ABA Intermediate 0.00 0.00 
MUC1 rs2070803 1 A 6 3886 4903 Asian 0.660 0.590 0.738 2.55E-13 ABA Intermediate 0.00 0.01 
KRTCAP2 rs4971088 1 T 3 1362 3101 Diffuse 0.608 0.526 0.703 1.60E-11 AAB Intermediate 0.02 0.96 
MTX1 rs2075570 1 G 5 3586 4603 Asian 0.672 0.596 0.759 1.44E-10 ABA Intermediate 0.01 0.90 
PPARG rs1805192 3 G 5 546 903 Mixed 2.265 1.695 3.027 3.20E-08 BAA Intermediate 0.78 1.00 
PPARG rs1805192 3 G 3 227 598 Caucasian 2.149 1.536 3.007 8.03E-06 BAA Intermediate 0.96 1.00 
PSCA rs2294008 8 T 4 1187 3162 Caucasian 1.337 1.177 1.519 8.51E-06 ABA Intermediate 0.45 0.99 
PSCA rs2976391 8 A 4 1921 2504 Asian 0.725 0.625 0.840 2.00E-05 ABA Intermediate 0.71 1.00 
FAM189B rs2072647 1 G 3 1362 3101 Diffuse 0.727 0.626 0.844 2.82E-05 ABA Intermediate 0.44 0.99 
PTGS2 rs20417 1 C 6 1464 3000 Asian 1.773 1.356 2.318 2.85E-05 BBB Intermediate 0.92 1.00 
THBS3 rs2066981 1 C 3 2649 3101 Asian 0.721 0.615 0.845 5.63E-05 ABA Intermediate 0.60 0.99 
IL1B rs1143634 2 T 4 434 450 HP positive 1.721 1.321 2.243 5.84E-05 BAB Intermediate 0.93 1.00 
IL17F rs763780 6 G 4 1760 2362 Asian 1.288 1.138 1.458 6.28E-05 AAB Intermediate 0.63 0.99 
YY1AP1 rs3738590 1 T 3 1362 3101 Diffuse 0.750 0.651 0.864 6.78E-05 ABA Intermediate 0.77 1.00 
KRTCAP2 rs4971088 1 T 3 2649 3101 Asian 0.725 0.618 0.852 9.04E-05 ABA Intermediate 0.87 1.00 
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TNF rs1800629 6 A 38 7896 12982 Mixed 1.166 1.074 1.267 2.67E-04 ABB Intermediate 0.26 0.99 
TLR4 rs4986790 9 G 3 774 1129 Non-cardia 2.022 1.351 3.026 6.17E-04 BBA Intermediate 0.99 1.00 
MDM2 rs2279744 12 G 4 778 2272 Cardia 1.384 1.133 1.690 0.001 ABB Intermediate 0.97 1.00 
TLR4 rs4986790 9 G 8 1859 3276 Caucasian 1.475 1.159 1.878 0.002 BBB Intermediate 0.98 1.00 
TNF rs1800629 6 A 19 3516 6604 Caucasian 1.187 1.065 1.322 0.002 ABA Intermediate 0.76 1.00 
IL1B rs16944 2 T 9 644 4867 Cardia 1.199 1.066 1.349 0.003 AAB Intermediate 0.83 1.00 
IL8 rs4073 4 A 8 1058 2620 Intestinal 1.240 1.077 1.428 0.003 ABA Intermediate 0.95 1.00 
ABO rs8176719 9 A (vs AB) 13 4696 620332 Caucasian 1.234 1.068 1.427 0.004 ABB Intermediate 0.96 1.00 
TNF rs1799724 6 T 7 1503 2517 Asian 1.189 1.043 1.355 0.010 BAA Intermediate 0.94 1.00 
TLR4 rs4986790 9 G 9 1919 3438 Mixed 1.433 1.089 1.886 0.010 BBB Intermediate 0.99 1.00 
IL10 rs1800871 1 T 3 78 399 Diffuse 0.567 0.367 0.875 0.010 BAB Intermediate 0.99 1.00 
EPHX1 rs1051740 1 C 3 427 1401 Caucasian 1.236 1.049 1.456 0.011 BAB Intermediate 0.98 1.00 
IGFBP3 rs2854744 7 C 3 1100 1338 Mixed 1.181 1.026 1.360 0.020 BAB Intermediate 0.98 1.00 
TP53 rs17878362 17 ins 3 342 635 Mixed 1.373 1.051 1.793 0.020 BAB Intermediate 0.99 1.00 
PRKAA1 rs13361707 5 C 3 1113 5261 Cardia 1.177 1.025 1.350 0.020 AAB Intermediate 0.97 1.00 
TIMP2 rs2277698 17 T 3 692 685 Mixed 0.807 0.669 0.975 0.026 BAB Intermediate 0.99 1.00 
IL8 rs2227306 4 T 4 348 1040 Asian 1.225 1.017 1.476 0.032 BAB Intermediate 0.99 1.00 
TNF rs1800629 6 A 7 1239 4520 Cardia 1.180 1.010 1.379 0.037 BAB Intermediate 0.98 1.00 
TNF rs1800629 6 A 8 1338 3836 Diffuse 1.262 1.010 1.578 0.041 BBB Intermediate 0.99 1.00 
KIAA0907 rs625658 1 C 3 1362 3101 Diffuse 0.842 0.713 0.993 0.042 ABB Intermediate 0.99 1.00 
 
Chr: chromosome; sOR: summary odds ratio; LL: sOR 95% lower level; UL: sOR 95% upper level; Venice criteria: A (high), B (moderate), C (weak) credibility for 3 
parameters (amount of evidence, heterogeneity and bias; see text for more details); level of evidence: overall level of summary evidence according to the Venice criteria; 
FPRP: false positive report probability (at two levels of prior probability, see text for more details) 
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Table 2: Combination of independent polymorphisms (pairwise r2 < 0.1) to predict risk of gastric carcinoma. 
 
 
Gene Variant ID Target PAR (%) Joint PAR (%) Joint MAF NNS (ltr: 1%) NNS (ltr:5%) 
PSCA rs2294008 Non-cardia 15.3 
28.8 0.24 666 133 
PRKAA1 rs13361707 Non-cardia 16.0 
PLCE1 rs2274223 Asian 11.1 
37.1 0.12 990 198 TGFBR2 rs3087465 Asian 26.4 
GSTP1 rs1695 Asian 3.9 
CASP8 rs3834129 Mixed 19.0 
21.3 0.30 707 141 
TNF rs1799724 Mixed 2.9 
MUC1 rs2070803 Diffuse 36.5 
51.2 0.05 424 22 
PKLR rs3762272 Diffuse 23.2 
 
PAR: population attributable risk; MAF: minor allele frequency (in controls); NNS: number needed to screen; ltr: life-time risk 
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Table 3. Meta-analysis results: variants with non significant association to gastric cancer risk with a high or intermediate level of summary 
evidence   
 
Gene Variant ID Chr 
Risk 
Allele 
Datasets Cases Controls Ethnicity sOR LL UL P-value Power Heterogeneity Bias Evidence 
TGFB1 rs1800470 19 C 4 1011 1522 Caucasian 0.917 0.817 1.030 0.143 A A A High 
PLCE1 rs2274223 10 G 5 2078 5694 Non-cardia 1.067 0.977 1.165 0.151 A A A High 
IL4 rs2243250 5 T 8 1878 3098 Mixed 1.063 0.953 1.187 0.271 A A A High 
IL1B rs16944 2 T 22 1725 7989 Diffuse 1.024 0.944 1.111 0.568 A A A High 
IL1B rs1143627 2 C 14 1199 3429 Diffuse 1.103 1.000 1.217 0.050 B A B Intermediate 
GSTM1 wild/null 1 null 5 3081 3322 Non-cardia 1.090 0.998 1.190 0.056 A A B Intermediate 
IL10 rs1800871 1 T 15 2756 5075 Mixed 0.903 0.810 1.006 0.063 A B B Intermediate 
CD14 rs2569190 5 C 6 1231 2408 Non-cardia 1.119 0.977 1.281 0.105 B B B Intermediate 
GSTT1 wild/null 22 null 6 1736 3280 Intestinal 1.168 0.965 1.413 0.111 B B A Intermediate 
LTA rs909253 6 G 16 3197 6459 Mixed 1.072 0.981 1.172 0.125 A B B Intermediate 
MIR196a2 rs11614913 12 C 4 1343 3440 Diffuse 0.937 0.854 1.029 0.174 B A A Intermediate 
FAS rs2234767 10 A 7 1748 2695 Mixed 1.062 0.960 1.175 0.242 B A A Intermediate 
FAS rs2234767 10 A 6 1634 2235 Asian 1.067 0.957 1.190 0.242 B A B Intermediate 
IL4 rs2070874 5 C 4 1423 2741 Mixed 0.908 0.742 1.110 0.346 B B B Intermediate 
PTPN11 rs12229892 12 A 3 1361 2740 Asian 0.960 0.875 1.054 0.394 B A A Intermediate 
CDH1 rs16260 16 A 8 1585 3701 Intestinal 0.951 0.841 1.075 0.424 B A A Intermediate 
KIAA0907 rs625658 1 C 3 2649 3101 Asian 0.945 0.816 1.094 0.448 B B A Intermediate 
IL10 rs1800896 1 G 9 1880 3614 Caucasian 0.964 0.854 1.088 0.555 A B B Intermediate 
MTHFR rs1801131 1 C 13 3784 5029 Mixed 0.982 0.874 1.102 0.751 A B B Intermediate 
XRCC1 rs25487 19 A 16 3628 7866 Mixed 0.990 0.904 1.084 0.827 A B A Intermediate 
RUNX3 rs6672420 1 A 3 1322 2394 Asian 0.984 0.853 1.136 0.830 B B A Intermediate 
OGG1 rs1052133 3 G 14 2107 4223 Mixed 0.988 0.867 1.126 0.853 A B A Intermediate 
ERCC2 rs13181 19 C 8 1483 4251 Caucasian 1.007 0.922 1.101 0.876 B A B Intermediate 
 
Chr: chromosome; sOR: summary odds ratio; LL: sOR 95% lower level; UL: sOR 95% upper level; power, heterogeneity, bias: quality of evidence (A: high, B: moderate, C: 
weak) for 3 parameters (amount of evidence, heterogeneity and bias; see text for more details); evidence: overall level of summary evidence 
 
